CD8A and neoplasm: Phase I clinical studies revealed that ALT‐803 was well tolerated, increased expansion of NK cells (NCT01727076[162]) and CD8+ T cells (NCT01885897[163]), and promoted anti‐tumor activity (NCT02523469,[164] NCT02138734[165]) in cancer patients.